Sun Pharma Advanced Research Company Limited

NSEI:SPARC Stock Report

Market Cap: ₹65.4b

Sun Pharma Advanced Research Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Anilkumar Raghavan

Chief executive officer

₹69.6m

Total compensation

CEO salary percentagen/a
CEO tenure10.7yrs
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Jan 17
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Nov 14
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Sep 05
Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Jun 27
Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

Nov 23
Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Feb 08
If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

Dec 14
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

CEO

Anilkumar Raghavan (56 yo)

10.7yrs

Tenure

₹69,608,000

Compensation

Mr. Anilkumar Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant...

Leadership Team

NamePositionTenureCompensationOwnership
Anilkumar Raghavan
Chief Executive Officer10.7yrs₹69.61mno data
Anup Rathi
Chief Financial Officerless than a yearno datano data
Nitin Dharmadhikari
Chief Operating Officerless than a yearno datano data
Jaydeep Issrani
Senior General Manager of Business Developmentno datano datano data
Kajal Damania
Company Secretary & Compliance Officer1.3yrsno datano data
Shanta Gupta
Chief Human Resource Officer4.9yrsno datano data
Siu-Long Yao
Head Clinical Developmentless than a yearno datano data
Nitin Damle
Chief Innovation Officerno datano datano data
Yashoraj Zala
Head of Drug Delivery Systemsno datano datano data
Vikram Ramanathan
Head of Preclinical Development5.7yrsno datano data
Venkata Palle
Global Head of Drug Discovery & Preclinical Development1.8yrsno datano data
Shravanti Bhowmik
VP & Head Operations Managementless than a yearno datano data

1.3yrs

Average Tenure

Experienced Management: SPARC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Dilip Shanghvi
Chairman18.8yrs₹390.00k19.06%
₹ 12.5b
Robert Jay Spiegel
Independent Director4.5yrs₹630.00kno data
Bhavna Doshi
Independent Director10.2yrs₹660.00kno data
Thennati Rajamannar
Non-Executive Non-Independent Director17.5yrs₹300.00k0.011%
₹ 7.2m
Vidhi Shanghvi
Additional Non-Executive Non-Independent Directorless than a yearno datano data
Ferzaan Engineer
Independent Director7.6yrs₹630.00kno data
Mark Simon
Member of Advisory Board4yrs₹570.00kno data

7.6yrs

Average Tenure

66yo

Average Age

Experienced Board: SPARC's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 20:57
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sun Pharma Advanced Research Company Limited is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pankaj KaduAxis Capital Limited
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Anubhav AggarwalCredit Suisse